Ac-DNLD-AMC is a fluorogenic caspase-3 substrate.

AC5 inhibitor C90 is a novel potent, selective adenylyl cyclase type 5 (AC5) inhibitor with IC50 of 30 nM, >5-fold selectivity over AC2 and AC6 subtypes.

AC-4-130 is a novel, potent STAT5 SH2 domain inhibitor, binds to and efficiently blocks STAT5 activation and subsequent transcriptional activity, shows high selectivity for STAT5 over STAT1 and STAT3.

AC261066 (AC-261066, AC261) is a potent, selective, orally available RARβ2 agonist with pEC50 of 8.1, displays selectivity over RARβ1, RARα and RARγ (pEC50=6.4, 6.2 and 6.3).

AC260584 is an M1 muscarinic receptor allosteric agonist with a pEC50 of 7.6.

ABTL0812 is a novel first-in-class, small molecule that inhibits the Akt/mTORC1 axis and shows antiproliferative effect on tumor cells.

ABT-288 is a potent, selective and competitive antagonist of H3 receptor with Ki of 1.9/8.2 nM for human/rat H3 respectively.

ABT-107 is a potent and selective α7 nAChR agonist with Ki of 0.2-0.6 nM for rat or human cortex α7 nAChRs.

ABT-102 is a potent, highly selective, orally active TRPV1 antagonist that inhibits agonist-evoked increases in intracellular Ca(2+) levels with IC50 of 5-7 nM.

ABT-100 (ABT100) is a highly selective, potent, orally bioavailable inhibitor of farnesyltransferase (FTase).

ABT-089 (Pozanicline) is a potent, selective α4β2 nAChR agonist with Ki of 16 nM.

ABT-080 is a potent FLAP inhibitor that inhibits ionophore-stimulated LTB(4) formation with with IC50 of 20 nM.

ABT-072 is a novel, orally bioavailable non-nucleoside HCV NS5B polymerase inhibitor with EC50 of 0.3 nM (GT1b).

ABP-A3(ABP A3) is an inhibitor of ubiquitin conjugation that targets ubiquitin and Nedd8 E1 enzymes.

Abn-CBD (Abnormal Cannabidiol) is a selective agonist of GPR55 receptor with EC50 of 2.5 uM, shows no significant activity against CB1 and CB2 receptors (EC50>30 uM).

ABMA is a novel broad-spectrum inhibitor of intracellular toxins and pathogens, efficiently protects cells against various toxins and pathogens including viruses, intracellular bacteria and parasite.

ABL-IN-29 is a picomolar ABL kinase inhibitor with IC50 of 0.06/0.11 nM for wt ABL and ABL T315I respectively..

Abiraterone (CB-7598) is a potent CYP17 inhibitor with IC50 of 2 nM.

Abeprazan is an acid pump inhibitor..

ABD345 is a small molecule inhibitor of RANKL signalling, inhibits TNF-induced NF-κB and MAPK activation and inflammation.

ABD328 (ABD-328) is an orally active, small molecule inhibitor of RANKL and TNF signalling that inhibits inflammation in vivo.

ABD-1970 (ABD1970) is a highly potent, selective Monoacylglycerol lipase (MGLL) inhibitor with IC50 of 13 nM (human MGLL).

ABC99 is a potent, selective inhibitor of the Wnt-deacylating enzyme serine hydrolase NOTUM with IC50 of 13 nM, shows excellent selectivity across the serine hydrolase family.

AAL(S) is the chiral deoxy analog of the FDA approved drug FTY720, has been shown to inhibit proliferation and apoptosis in several cancer cell lines by activating protein phosphatase 2A (PP2A)..

AAK1 inhibitor 25A is a potent, selective inhibitor of AAK1 and the closely related kinase BMP2K with Ki of 8 nM (AAK1).

AAK1 inhibitor 1 (SGC-AAK1-1) is a potent, selective inhibitor of AAK1 and BMP2K/BIKE ((BMP-2 inducible kinase)) that potently targets the ATP-binding site (AAK1 Ki =9.1 nM, BIKE Ki= 17 nM).

AAE871 (AAE-871) is a potent type I kinase inhibitor of FLT3 with IC50 of 34 nM, potently inhibits proliferation of FLT3-ITD- and D835Y-expressing cells (IC50<10 nM) through selective inhibition of FLT3 kinase activity..

AAD777 (NVP-AAD777.

AA-861 (Docebenone) is a potent, selective 5-Lipoxygenase (5-LO) inhibitor with IC50 of 0.8 uM.

aA highly potent, selective, non-competitive and centrally active mGluR1 antagonist with Ki of 0.34 nM.